Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

ASCEND-8: safety data of ceritinib with or without food in NSCLC

Prof Byoung Chul Cho - Yonsei Cancer Center, Seoul, Republic of Korea

ASCEND-8: safety data of ceritinib with or without food in NSCLC ( Prof Byoung Chul Cho - Yonsei Cancer Center, Seoul, Republic of Korea )

CheckMate142: Checkpoint combination therapy in first-line colorectal cancer

Dr Heinz-Josef J. Lenz - Keck School of Medicine of USC, Los Angeles, USA

CheckMate142: Checkpoint combination therapy in first-line colorectal cancer ( Dr Heinz-Josef J. Lenz - Keck School of Medicine of USC, Los Angeles, USA )

SOLO1: Maintenance olaparib in advanced BRCA ovarian cancer

Dr Kathleen N. Moore - The Stephenson Cancer Center, Oklahoma City, USA

SOLO1: Maintenance olaparib in advanced BRCA ovarian cancer ( Dr Kathleen N. Moore - The Stephenson Cancer Center, Oklahoma City, USA )

Lung highlights from ESMO 2018

Dr Federico Cappuzzo - AUSL della Romagna-Ravenna, Ravenna, Italy

Lung highlights from ESMO 2018 ( Dr Federico Cappuzzo - AUSL della Romagna-Ravenna, Ravenna, Italy )

Erlotinib for neoadjuvant treatment of EGFR NSCLC

Dr Wen-Zhao Zhong - Guangdong General Hospital & Guangdong Academy of Medical...

Erlotinib for neoadjuvant treatment of EGFR NSCLC ( Dr Wen-Zhao Zhong - Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China )

AURA 3: Mechanisms of osimertinib resistance in patients with EGFR T790M...

Dr Vassiliki A. Papadimitrakopoulou - University of Texas MD Anderson Cancer...

AURA 3: Mechanisms of osimertinib resistance in patients with EGFR T790M advanced NSCLC ( Dr Vassiliki A. Papadimitrakopoulou - University of Texas MD Anderson Cancer Center, Houston, USA )

20 year followup on high-dose chemo with HSCT in high-risk breast cancer

Dr Tessa Steenbruggen - Netherlands Cancer Institute, Amsterdam, Netherlands

20 year followup on high-dose chemo with HSCT in high-risk breast cancer ( Dr Tessa Steenbruggen - Netherlands Cancer Institute, Amsterdam, Netherlands )

Opportunities for biosimilars in practice and education

Prof Diana Lüftner- Humboldt University, Berlin, Germany

Opportunities for biosimilars in practice and education ( Prof Diana Lüftner- Humboldt University, Berlin, Germany )

Comment on the TRIBE-2 study on first and second-line treatment for metastatic...

Dr Filippo Pietrantonio - ‎IRCCS Istituto Nazionale dei Tumori Foundation...

Comment on the TRIBE-2 study on first and second-line treatment for metastatic colorectal cancer ( Dr Filippo Pietrantonio - ‎IRCCS Istituto Nazionale dei Tumori Foundation, Milan, Italy )

VALENTINO: Maintenance therapy in advanced CRC

Dr Filippo Pietrantonio - ‎IRCCS Istituto Nazionale dei Tumori Foundation...

VALENTINO: Maintenance therapy in advanced CRC ( Dr Filippo Pietrantonio - ‎IRCCS Istituto Nazionale dei Tumori Foundation, Milan, Italy )

Pan-cancer assessment of BRCA1/2 genomic alterations by comprehensive genomic...

Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, Utah

Pan-cancer assessment of BRCA1/2 genomic alterations by comprehensive genomic profiling of tissue and circulating tumour DNA ( Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, Utah )

The standard of care and progress so far with PARP inhibitors for ovarian cancer

Dr Susana Banerjee - The Institute of Cancer Research, London, UK

The standard of care and progress so far with PARP inhibitors for ovarian cancer ( Dr Susana Banerjee - The Institute of Cancer Research, London, UK )

More from ecancer